<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113288">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628432</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN11/LO/SALPINGOVA</org_study_id>
    <nct_id>NCT01628432</nct_id>
  </id_info>
  <brief_title>Effect of Salpingectomy During Conservative Hysterectomy</brief_title>
  <acronym>SALPINGOVA</acronym>
  <official_title>Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the effect of bilateral salpingectomy associated with conservative
      hysterectomy on ovarian function to the standard hysterectomy with conservation of both
      ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation, complications,
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hysterectomy is one of the most common gynecologic procedures performed in clinical
      practice. In this study we focused on non menopausal patients under 52 years having
      hysterectomies for benign disease : uterine leiomyomas, adenomyosis, endometriosis,
      dysfunctional uterine bleeding, genital prolapse, cervical dysplasia... with failure of
      conservative treatment.

      the standard procedure during hysterectomy with conservation of the ovaries has been the
      preservation of fallopian tubes with the clamps placed as close to the uterine corpus as
      possible. this is suggested to decrease interference with the vascular structures in the
      mesosalpinx and mesovarium. however it is unclear whether tubal conservation at the time of
      hysterectomy has any influence on ovarian blood flow or ovarian reserve. another point to be
      considered is the occurrence of post-hysterectomy carcinoma in the preserved fallopian tube,
      theoretically, these cases could be prevented if tubal excision is performed during
      hysterectomy The study compares the effect of bilateral salpingectomy associated with
      conservative hysterectomy on ovarian function to the standard hysterectomy with conservation
      of both ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation,
      complications, quality of life.

      impact of treatments on ovarian reserve are tested by measuring AMH at baseline and 3 days,
      6 weeks and 6, 12 months after surgeries.

      quality of life is also assessed at these time points, with a questionnaire (Women Health
      Questionnaire WHQ).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with more than 20% diminution of AMH logarithm at one year (12 months)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH measurement at 3 days, 6 weeks, and 6, 12 months after hysterectomy endovaginal ultrasound evaluation of the ovarian volume and vascularisation quality of life (WHQ questionnaire) reintervention procedures complications</measure>
    <time_frame>day3, week 6, month 6 and month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Genital Diseases, Female</condition>
  <condition>Hysterotomy; Affecting Fetus</condition>
  <condition>Leiomyomata Uteri</condition>
  <condition>Adenomyosis, Endometriosis</condition>
  <condition>Dysfunctional Uterine Bleeding</condition>
  <condition>Cervical Dysplasia</condition>
  <condition>Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>conservative hysterectomy I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bilateral salpingectomy during hysterectomy with conservation of the ovaries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conservative hysterectomy II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard conservative hysterectomy with conservation of both ovaries and tubes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conservative hysterectomy I</intervention_name>
    <description>conservative hysterectomy for benign disease</description>
    <arm_group_label>conservative hysterectomy I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conservative hysterectomy II</intervention_name>
    <description>bilateral salpingectomy during hysterectomy without conservation of the ovaries</description>
    <arm_group_label>conservative hysterectomy II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years and less than 52 years

          -  indication of a conservative hysterectomy for benign disease

          -  signed informed consent

          -  non menopausal women (AMH &gt;0,21 ng/ml)

        Exclusion Criteria:

          -  pregnancy

          -  desire of future pregnancy

          -  menopausal status

          -  patient unable to give informed consent

          -  any physical or psychiatric condition that could impair with patient's ability to
             cooperate with post operative data collection

          -  previous salpingo and /or oophorectomy (unilateral or bilateral)

          -  genital cancer disease or atypical endometrial hyperplasia

          -  hyperandrogenia

          -  any ovarian mass that needs surgical exploration

          -  any immunotherapy that could interfere with immunological tests
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lobna OULDAMER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lobna OULDAMER, MD</last_name>
    <phone>(33)2.47.47.48.44</phone>
    <email>l.ouldamer@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine FREMONT</last_name>
    <phone>(33) 2.18.37.05.35</phone>
    <email>fremont@mrd.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DESCAMPS, MD</last_name>
      <phone>(33) 2 41 35 48 99</phone>
      <email>phdescamps@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe DESCAMPS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Kremlin Bicetre</city>
        <zip>94 275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine GIRAUDET, MD</last_name>
      <phone>(33) 3.20.44.66.38</phone>
      <email>Geraldine.GIRAUDET@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Geraldine GIRAUDET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GOLFIER, PhD</last_name>
      <phone>(33) 4.78.86.41.79</phone>
      <email>francois.golfier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>François GOLFIER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier FRITEL, PhD</last_name>
      <phone>(33) 5 49 44 33.60</phone>
      <email>xavier.fritel@univ-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier FRITEL, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean LEVEQUE, MD</last_name>
      <phone>(33) 2 99 26 71 71</phone>
      <email>jean.leveque@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean LEVEQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lobna OULDAMER, MD</last_name>
      <phone>(33) 2.47.47.48.44</phone>
      <email>l.ouldamer@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Catherine FREMONT</last_name>
      <phone>(33) 2.18.37.05.35</phone>
      <email>fremont@med.univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Henri MARRET, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas HEBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles BODY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annie JACQUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 5, 2016</lastchanged_date>
  <firstreceived_date>June 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
